Ceplene (histamine) / Immune Pharma - LARVOL DELTA

An Observational Study to Determine the Real-Life Effectiveness of MP-AzeFlu® in Austrian Patients with Persistent Allergic Rhinitis. (PubMed, Drugs Real World Outcomes) - "Many patients in Austria live with uncontrolled persistent AR despite treatment. MP-AzeFlu provides effective and rapid control of persistent AR in a real-world Austrian setting."

Journal • Observational data • Allergic Rhinitis • Immunology • Inflammation

A double-blind, placebo-controlled trial of the efficacy and safety of two doses of azelastine hydrochloride in perennial allergic rhinitis. (PubMed, Front Allergy) - P3 | "It effectively relieves nasal and non-nasal symptoms. ClinicalTrials.gov, identifier: NCT00712920."

Journal • Allergic Rhinitis • Immunology • Inflammation

MP-AzeFlu in Moderate-to-Severe Allergic Rhinitis: A Literature Review. (PubMed, Int Arch Allergy Immunol) - "Treatment of AR with MP-AzeFlu results in effective, sustained relief of nasal and ocular symptoms, and faster onset and time to control compared with intranasal azelastine or fluticasone propionate...Furthermore, MP-AzeFlu significantly improves patient quality of life. MP-AzeFlu is a currently available combination that may satisfy all these patient needs and expectations."

Journal • Review • Allergic Rhinitis • Immunology

Allergic Rhinitis Therapy Decisions During a Routine Consultation: A Multicenter, Cross-Sectional Survey. (PubMed, J Asthma Allergy) - "Many patients suffering from acute AR symptoms consulted with their physician because of insufficient medications. Not all patients with uncontrolled symptoms received a step-up in treatment, underscoring the need for improved physician education to enhance AR management and control in accordance with consensus treatment guidelines."

Clinical • Journal • Allergic Rhinitis • Immunology

EpiCept provides clinical and business update on Ceplene program (Pharmalive) -

Announces New Initiatives to Expand Label, Drive Product Adoption

Maintenance Therapy With Ceplene® (Histamine) and IL-2 on Immune Response and MRD in Acute Myeloid Leukemia (clinicaltrials.gov) - P4; N=84; Completed; Sponsor: MEDA Pharma GmbH & Co. KG; Active, not recruiting ➔ Completed

Clinical • IO Biomarker • Trial completion

Maintenance Therapy With Ceplene® (Histamine) and IL-2 on Immune Response and MRD in Acute Myeloid Leukemia (clinicaltrials.gov) - P4; N=150; Active, not recruiting; Sponsor: MEDA Pharma GmbH & Co. KG; Recruiting ➔ Active, not recruiting

Clinical • Enrollment closed • IO Biomarker

Maintenance Therapy With Ceplene® (Histamine) and IL-2 on Immune Response and MRD in Acute Myeloid Leukemia (clinicaltrials.gov) - P4; N=84; Active, not recruiting; Sponsor: MEDA Pharma GmbH & Co. KG; Trial completion date: Jun 2015 ➔ Jul 2014

Clinical • IO Biomarker • Trial completion date

Maintenance Therapy With Ceplene® (Histamine) and IL-2 on Immune Response and MRD in Acute Myeloid Leukemia (clinicaltrials.gov) - P4; N=84; Active, not recruiting; Sponsor: MEDA Pharma GmbH & Co. KG; N=150 ➔ 84

Clinical • Enrollment change • IO Biomarker

Maintenance Therapy With Ceplene® (Histamine) and IL-2 on Immune Response and MRD in Acute Myeloid Leukemia (clinicaltrials.gov) - P4; N=84; Active, not recruiting; Sponsor: MEDA Pharma GmbH & Co. KG; Trial primary completion date: Jun 2015 ➔ Jul 2014

Clinical • IO Biomarker • Trial primary completion date

Highlights & Key results: Relapse Prevention by Ceplene/IL-2 in Molecular Subgroups of AML (ISAL 2019) - No abstract available.

Highlights & Key Results: Immune Activation during Immunotherapy with Ceplene/IL2: Implications for Relapse risk and Survival in AML (ISAL 2019) - No abstract available.